PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION

Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain crosslinked amine polymers and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons and/or chloride ions from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human. 2. The pharmaceutical composition of where the crosslinked amine polymer has (i) an equilibrium proton binding capacity of at least 5 mmol/g and a chloride ion binding capacity of at least 5 mmol/g in an aqueous simulated gastric fluid buffer (“SGF”) containing 35 mM NaCl and 63 mM HCl at pH 1.2 and 37° C. claim 1 , and (ii) an equilibrium swelling ratio in deionized water of about 2 or less.3. The pharmaceutical composition of wherein the crosslinked amine polymer has an equilibrium chloride binding capacity of at least 10 mmol/g in an aqueous simulated gastric fluid buffer (“SGF”) containing 35 mM NaCl and 63 mM HCl at pH 1.2 and 37° C.4. The pharmaceutical composition of wherein the crosslinked amine polymer binds more chloride than any one of the interfering anions in the interfering ion buffer claim 1 , the interfering ions are phosphate claim 1 , citrate and taurocholate ions and the interfering ion buffer is a buffered solution at pH 6.2 including 36 mM chloride claim 1 , 7 mM phosphate claim 1 , 1.5 mM citrate claim 1 , and 5 mM taurocholate5. The pharmaceutical composition of wherein R claim 1 , Rand Rare independently hydrogen claim 1 , alkyl claim 1 , alkenyl claim 1 , allyl claim 1 , vinyl claim 1 , aryl claim 1 , aminoalkyl claim 1 , alkanol claim 1 , haloalkyl claim 1 , hydroxyalkyl claim 1 , ethereal claim 1 , heteroaryl or heterocyclic provided claim 1 , however claim 1 , at least one of R claim 1 , Rand Ris other than hydrogen.6. The pharmaceutical composition of ...

PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION

Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain crosslinked amine polymers and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons and/or chloride ions from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human. 1. A process for the preparation of a crosslinked amine polymer , the process comprising (i) swelling a preformed amine polymer with a swelling agent , (ii) dispersing the preformed amine polymer in a reaction mixture comprising a dispersing solvent , a crosslinking agent , and the swelling agent , and (iii) crosslinking the preformed amine polymer in the reaction mixture to form the crosslinked amine polymer , wherein the preformed amine polymer is crosslinked and has an absorption capacity for the swelling agent , and the amount of swelling agent in the reaction mixture is less than the absorption capacity of the preformed amine polymer for the swelling agent.2. The process of wherein the process further comprises deprotonating the preformed amine polymer with a base before it is swollen with the swelling agent.3. The process of or wherein the crosslinks in the preformed amine polymer are primarily carbon-carbon crosslinks and nitrogen-nitrogen crosslinks are primarily formed in the crosslinking step.4. The process of any of the preceding claims wherein the preformed amine polymer has a chloride binding capacity of at least 10 mmol/g in Simulated Gastric Fluid (“SGF”) and a Swelling Ratio in the range of 2 to 10 claim 1 , and the crosslinked amine polymer has a binding capacity for phosphate claim 1 , citrate and/or taurocholate in SIB or SOB that is less than the binding capacity of the preformed amine polymer for phosphate claim 1 , citrate and/or taurocholate in that same ...

COMPOSITIONS FOR AND METHODS OF TREATING ACID-BASE DISORDERS

Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain nonabsorbable compositions and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons, the conjugate base of a strong acid and/or a strong acid from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human.

PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION

Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain crosslinked amine polymers and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons and/or chloride ions from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human. 2. The pharmaceutical composition of where the crosslinked amine polymer has (i) an equilibrium proton binding capacity of at least 5 mmol/g and a chloride ion binding capacity of at least 5 mmol/g in an aqueous simulated gastric fluid buffer (“SGF”) containing 35 mM NaCl and 63 mM HCl at pH 1.2 and 37° C. claim 1 , and (ii) an equilibrium swelling ratio in deionized water of about 2 or less.3. The pharmaceutical composition of wherein the crosslinked amine polymer has an equilibrium chloride binding capacity of at least 10 mmol/g in an aqueous simulated gastric fluid buffer (“SGF”) containing 35 mM NaCl and 63 mM HCl at pH 1.2 and 37° C.4. The pharmaceutical composition of wherein the crosslinked amine polymer binds more chloride than any one of the interfering anions in the interfering ion buffer claim 1 , the interfering ions are phosphate claim 1 , citrate and taurocholate ions and the interfering ion buffer is a buffered solution at pH 6.2 including 36 mM chloride claim 1 , 7 mM phosphate claim 1 , 1.5 mM citrate claim 1 , and 5 mM taurocholate5. The pharmaceutical composition of wherein R claim 1 , Rand Rare independently hydrogen claim 1 , alkyl claim 1 , alkenyl claim 1 , allyl claim 1 , vinyl claim 1 , aryl claim 1 , aminoalkyl claim 1 , alkanol claim 1 , haloalkyl claim 1 , hydroxyalkyl claim 1 , ethereal claim 1 , heteroaryl or heterocyclic provided claim 1 , however claim 1 , at least one of R claim 1 , Rand Ris other than hydrogen.6. The pharmaceutical composition of ...

COMPOSITIONS FOR AND METHODS OF TREATING ACID-BASE DISORDERS

Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain nonabsorbable compositions and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons, the conjugate base of a strong acid and/or a strong acid from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human. 1. A method of treating an individual afflicted with an acid-base disorder characterized by a baseline serum bicarbonate value of less than 22 mEq/l , the method comprising oral administration of a daily dose of a pharmaceutical composition having the capacity to bind at least 5 mEq of a target species as it transits the digestive system to achieve a clinically significant increase in the serum bicarbonate value of at least 1 mEq/l from baseline within a treatment period not greater than 1 month , the target species being selected from the group consisting of protons , strong acids , and conjugate bases of strong acids.2. A method of treating an individual afflicted with an acid-base disorder characterized by a baseline serum bicarbonate value of less than 22 mEq/l , the method comprising oral administration of a pharmaceutical composition , wherein the pharmaceutical composition given orally binds at least 5 mEq per day on average of a target species in the digestive system , said oral administration achieving a clinically significant increase in the serum bicarbonate value of at least 1 mEq/l from baseline within a treatment period not greater than 1 month , the target species being selected from the group consisting of protons , strong acids , and conjugate bases of strong acids.3. A method of treating an individual afflicted with an acid-base disorder characterized by a baseline serum bicarbonate value of less than 22 mEq/l , the method ...

PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION

Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain crosslinked amine polymers and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons and/or chloride ions from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human. 2. The pharmaceutical composition of where the crosslinked amine polymer has (i) an equilibrium proton binding capacity of at least 5 mmol/g and a chloride ion binding capacity of at least 5 mmol/g in an aqueous simulated gastric fluid buffer (“SGF”) containing 35 mM NaCl and 63 mM HCl at pH 1.2 and 37° C. claim 1 , and (ii) an equilibrium swelling ratio in deionized water of about 2 or less.3. The pharmaceutical composition of wherein the crosslinked amine polymer has an equilibrium chloride binding capacity of at least 10 mmol/g in an aqueous simulated gastric fluid buffer (“SGF”) containing 35 mM NaCl and 63 mM HCl at pH 1.2 and 37° C.4. The pharmaceutical composition of wherein the crosslinked amine polymer binds more chloride than any one of the interfering anions in the interfering ion buffer claim 1 , the interfering ions are phosphate claim 1 , citrate and taurocholate ions and the interfering ion buffer is a buffered solution at pH 6.2 including 36 mM chloride claim 1 , 7 mM phosphate claim 1 , 1.5 mM citrate claim 1 , and 5 mM taurocholate5. The pharmaceutical composition of wherein R claim 1 , Rand Rare independently hydrogen claim 1 , alkyl claim 1 , alkenyl claim 1 , allyl claim 1 , vinyl claim 1 , aryl claim 1 , aminoalkyl claim 1 , alkanol claim 1 , haloalkyl claim 1 , hydroxyalkyl claim 1 , ethereal claim 1 , heteroaryl or heterocyclic provided claim 1 , however claim 1 , at least one of R claim 1 , Rand Ris other than hydrogen.6. The pharmaceutical composition of ...

Crosslinked poly(allylamine) polymer pharmaceutical compositions

Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain crosslinked amine polymers and may be used, for example, to treat diseases or other metabolic conditions in which removal of a target species from the gastrointestinal tract would provide physiological benefits.

PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION

Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain crosslinked amine polymers and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons and/or chloride ions from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human. 2. The pharmaceutical composition of where the crosslinked amine polymer has (i) an equilibrium proton binding capacity of at least 5 mmol/g and a chloride ion binding capacity of at least 5 mmol/g in an aqueous simulated gastric fluid buffer (“SGF”) containing 35 mM NaCl and 63 mM HCl at pH 1.2 and 37° C. claim 1 , and (ii) an equilibrium swelling ratio in deionized water of about 2 or less.3. The pharmaceutical composition of wherein the crosslinked amine polymer has an equilibrium chloride binding capacity of at least 10 mmol/g in an aqueous simulated gastric fluid buffer (“SGF”) containing 35 mM NaCl and 63 mM HCl at pH 1.2 and 37° C.4. The pharmaceutical composition of wherein the crosslinked amine polymer binds more chloride than any one of the interfering anions in the interfering ion buffer claim 1 , the interfering ions are phosphate claim 1 , citrate and taurocholate ions and the interfering ion buffer is a buffered solution at pH 6.2 including 36 mM chloride claim 1 , 7 mM phosphate claim 1 , 1.5 mM citrate claim 1 , and 5 mM taurocholate5. The pharmaceutical composition of wherein R claim 1 , Rand Rare independently hydrogen claim 1 , alkyl claim 1 , alkenyl claim 1 , allyl claim 1 , vinyl claim 1 , aryl claim 1 , aminoalkyl claim 1 , alkanol claim 1 , haloalkyl claim 1 , hydroxyalkyl claim 1 , ethereal claim 1 , heteroaryl or heterocyclic provided claim 1 , however claim 1 , at least one of R claim 1 , Rand Ris other than hydrogen.6. The pharmaceutical composition of ...

PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION

Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain crosslinked amine polymers and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons and/or chloride ions from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human. 130-. (canceled)32. The pharmaceutical composition for use according to wherein the crosslinked amine polymer has an equilibrium swelling ratio in deionized water of 4 or less claim 31 , or 3 or less claim 31 , or 2 or less claim 31 , or 1.5 or less claim 31 , or 1 or less.33. The pharmaceutical composition for use according to wherein R claim 31 , Rand Rare independently hydrogen claim 31 , alkyl claim 31 , alkenyl claim 31 , allyl claim 31 , vinyl claim 31 , aryl claim 31 , aminoalkyl claim 31 , alkanol claim 31 , haloalkyl claim 31 , hydroxyalkyl claim 31 , ethereal claim 31 , heteroaryl or heterocyclic provided claim 31 , however claim 31 , each of R claim 31 , Rand Ris not hydrogen claim 31 , or more specifically the pharmaceutical composition for use according to any preceding claim wherein R claim 31 , Rand Rare independently hydrogen claim 31 , aliphatic or heteroaliphatic provided claim 31 , however claim 31 , at least one of R claim 31 , Rand Ris other than hydrogen.354. The pharmaceutical composition for use according to wherein Rand Rare independently hydrogen claim 34 , alkyl claim 34 , alkenyl claim 34 , allyl claim 34 , vinyl claim 34 , aryl claim 34 , aminoalkyl claim 34 , alkanol claim 34 , haloalkyl claim 34 , hydroxyalkyl claim 34 , ethereal claim 34 , heteroaryl or heterocyclic claim 34 , or more specifically the pharmaceutical composition of claim wherein Rand Rare independently hydrogen claim 34 , aliphatic or heteroaliphatic.3766. The pharmaceutical ...

HCL-BINDING COMPOSITIONS FOR AND METHODS OF TREATING ACID-BASE DISORDERS

Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain nonabsorbable compositions and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons, the conjugate base of a strong acid and/or a strong acid from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human. 1. A method of treating an individual afflicted with an acid-base disorder characterized by a baseline serum bicarbonate value of less than 22 mEq/l , the method comprising oral administration of a daily dose of a pharmaceutical composition having the capacity to bind at least 5 mEq of HCl as it transits the digestive system to achieve a clinically significant increase in the serum bicarbonate value of at least 1 mEq/l from baseline within a treatment period not greater than 1 month.2. A method of treating an individual afflicted with an acid-base disorder characterized by a baseline serum bicarbonate value of less than 22 mEq/l , the method comprising oral administration of a pharmaceutical composition , wherein the pharmaceutical composition given orally binds at least 5 mEq per day on average of HCl in the digestive system , said oral administration achieving a clinically significant increase in the serum bicarbonate value of at least 1 mEq/l from baseline within a treatment period not greater than 1 month.3. A method of increasing serum bicarbonate levels in an individual afflicted with an acid-base disorder , the method comprising oral administration of a pharmaceutical composition to increase the individual's serum bicarbonate levels wherein:(i) the pharmaceutical composition binds HCl in the individual's digestive system when given orally and(ii) the pharmaceutical composition increases the serum bicarbonate level by at least 3 mEq/l in ...

COMPOSITIONS FOR TREATING ACID-BASE DISORDERS

Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain nonabsorbable compositions and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons, the conjugate base of a strong acid and/or a strong acid from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human. 1237-. (canceled)239. The method according to claim 238 , wherein the patient's serum bicarbonate level is less than(a) 17 mEq/L,(b) 16 mEq/L, or(c) 15 mEq/L prior to treatment.240. The method according to wherein said patient's serum bicarbonate value is increased by at least 1 mEq/L over 15 days of treatment.241. The method according to wherein the treatment increases the individual's serum bicarbonate value to an increased serum bicarbonate value that exceeds the baseline serum bicarbonate value by:(a) at least 1.5 mEq/l,(b) at least 2 mEq/l,(c) at least 2.5 mEq/l,(d) at least 3 mEq/l,(e) at least 3.5 mEq/l, or(f) at least 4 mEq/l.242. The method according to wherein the adult human patient has chronic kidney disease.243. The method according to wherein the nonabsorbable composition is characterized by a chloride ion binding capacity in a Simulated Small Intestine Inorganic Buffer (“SIB”) assay of(a) at least 2.5 mEq/g,(b) at least 3 mEq/g,(c) at least 3.5 mEq/g,(d) at least 4 mEq/g,(e) at least 4.5 mEq/g, or(f) at least 5 mEq/g.244. The method according to wherein the crosslinked amine polymer has an equilibrium swelling ratio in deionized water of(a) about 1.5 or less, or(b) about 1 or less.245. The method according to wherein the crosslinked amine polymer has a chloride ion to phosphate ion binding molar ratio of(a) at least 0.5:1, respectively,(b) at least 1:1, respectively, or{'sub': 2', '4, '(c) at least 2:1, respectively, in an ...

PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION

Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain crosslinked amine polymers and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons and/or chloride ions from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human. 2. The pharmaceutical composition of where the crosslinked amine polymer has (i) an equilibrium proton binding capacity of at least 5 mmol/g and a chloride ion binding capacity of at least 5 mmol/g in an aqueous simulated gastric fluid buffer (“SGF”) containing 35 mM NaCl and 63 mM HCl at pH 1.2 and 37° C. claim 1 , and (ii) an equilibrium swelling ratio in deionized water of about 2 or less.3. The pharmaceutical composition of wherein the crosslinked amine polymer has an equilibrium chloride binding capacity of at least 10 mmol/g in an aqueous simulated gastric fluid buffer (“SGF”) containing 35 mM NaCl and 63 mM HCl at pH 1.2 and 37° C.4. The pharmaceutical composition of wherein the crosslinked amine polymer binds more chloride than any one of the interfering anions in the interfering ion buffer claim 1 , the interfering ions are phosphate claim 1 , citrate and taurocholate ions and the interfering ion buffer is a buffered solution at pH 6.2 including 36 mM chloride claim 1 , 7 mM phosphate claim 1 , 1.5 mM citrate claim 1 , and 5 mM taurocholate5. The pharmaceutical composition of wherein R claim 1 , Rand Rare independently hydrogen claim 1 , alkyl claim 1 , alkenyl claim 1 , allyl claim 1 , vinyl claim 1 , aryl claim 1 , aminoalkyl claim 1 , alkanol claim 1 , haloalkyl claim 1 , hydroxyalkyl claim 1 , ethereal claim 1 , heteroaryl or heterocyclic provided claim 1 , however claim 1 , at least one of R claim 1 , Rand Ris other than hydrogen.6. The pharmaceutical composition of ...

COMPOSITIONS FOR TREATING ACID-BASE DISORDERS

Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain nonabsorbable compositions and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons, the conjugate base of a strong acid and/or a strong acid from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human. 1. A composition for use in a method of treating metabolic acidosis in an adult human patient wherein in said treatment 0.1-12 g of said composition is administered to the patient per day , said composition being a nonabsorbable composition having the capacity to remove protons from the patient , wherein the nonabsorbable composition is characterized by a chloride ion binding capacity of at least 2.5 mEq/g in a Simulated Small Intestine Inorganic Buffer (“SIB”) assay.2. A composition for use in a method of treating metabolic acidosis in an adult human patient , said patient having a serum bicarbonate level of less than 20 mEq/L prior to treatment , said composition being a nonabsorbable composition having the capacity to remove protons from the patient.3. The composition for use according to claim 2 , wherein the patient's serum bicarbonate level is less than 19 mEq/L prior to treatment.4. The composition for use according to claim 2 , wherein the patient's serum bicarbonate level is less than 18 mEq/L prior to treatment.5. The composition for use according to claim 2 , wherein the patient's serum bicarbonate level is less than 17 mEq/L prior to treatment.6. The composition for use according to claim 2 , wherein the patient's serum bicarbonate level is less than 16 mEq/L prior to treatment.7. The composition for use according to claim 2 , wherein the patient's serum bicarbonate level is less than 15 mEq/L prior to treatment.8. The composition ...

PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION

Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain crosslinked amine polymers and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons and/or chloride ions from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human. 230.-. (canceled)32. The method of claim 31 , wherein Rand Rare independently hydrogen claim 31 , aliphatic or heteroaliphatic.33. The method of claim 1 , wherein the patient is a human patient.34. The method according to claim 1 , wherein the serum bicarbonate is controlled or normalized.35. The method according to claim 1 , wherein the pharmaceutical composition is administered to the patient as a daily dose.36. The method according to claim 35 , wherein the daily dose administered is less than 20 g.37. The method according to claim 35 , wherein the daily dose administered is less than 15 g.38. The method according to claim 35 , wherein the daily dose administered is less than 10 g.39. The method according to claim 35 , wherein the daily dose administered is less than 5 g.40. The method according to claim 35 , wherein the daily dose is administered once a day.41. The method according to claim 35 , wherein the daily dose results in a sustained serum bicarbonate increase of ≥3 mEq/L.42. The method according to claim 35 , wherein a daily dose of 10 g or less per day results in an increase in serum bicarbonate of ≥3 mEq/L.43. The method according to claim 31 , wherein the pharmaceutical composition is administered to the patient as a daily dose.44. The method according to claim 43 , wherein the daily dose administered is less than 20 g.45. The method according to claim 43 , wherein the daily dose administered is less than 15 g.46. The method according to claim 43 , wherein the ...

CROSSLINKED POLY(ALLYLAMINE) POLYMER PHARMACEUTICAL COMPOSITIONS

Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain crosslinked amine polymers and may be used, for example, to treat diseases or other metabolic conditions in which removal of a target species from the gastrointestinal tract would provide physiological benefits. 1. A crosslinked poly(allylamine) polymer in bead form comprising the residues of a monoallylamine or a salt thereof and a multiallylamine or a salt thereof wherein (i) the crosslinked poly(allylamine) polymer has a swelling ratio of less than 2 and (ii) spallyl carbons comprised by the crosslinked poly(allylamine) polymer constitute less than 1.0% of the total number of carbon atoms comprised by the crosslinked poly(allylamine) polymer.4. The crosslinked poly(allylamine) polymer of wherein each Ris independently hydrogen claim 2 , aliphatic claim 2 , or heteroaliphatic.5. The crosslinked poly(allylamine) polymer of wherein the crosslinked poly(allylamine) polymer comprises the residue of a dihaloalkane.6. The crosslinked poly(allylamine) polymer of wherein the crosslinked poly(allylamine) polymer comprises the residue of 1 claim 1 ,2-dibromoethane claim 1 , 1 claim 1 ,2-dichloroethane claim 1 , 1-bromo-2-chloroethane claim 1 , 1 claim 1 ,3-dichloropropane claim 1 , 1 claim 1 ,3-dibromopropane claim 1 , and 1-bromo-3-chloropropane.7. The crosslinked poly(allylamine) polymer of wherein spallyl carbons comprised by the crosslinked poly(allylamine) polymer constitute less than 1% of the total number of carbon atoms comprised by the crosslinked poly(allylamine) polymer.8. The crosslinked poly(allylamine) polymer of wherein spallyl carbons comprised by the crosslinked poly(allylamine) polymer constitute less than 0.1% of the total number of carbon atoms comprised by the crosslinked poly(allylamine) polymer.9. The crosslinked poly(allylamine) polymer of wherein the crosslinked poly(allylamine) ...

PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION

Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain crosslinked amine polymers and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons and/or chloride ions from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human. 230.-. (canceled) This application is a continuation of U.S. application Ser. No. 15/715,934 filed on Sep. 26, 2017; which is a continuation of Ser. No. 14/944,844 filed on Nov. 18, 2015 and issued as U.S. Pat. No. 9,925,214 on Mar. 27, 2018; which is a continuation of U.S. application Ser. No. 14/311,852 filed on Jun. 23, 2014 and issued as U.S. Pat. No. 9,205,107 on Dec. 8, 2015; which is a continuation of International Application No. PCT/US2014/041152, filed on Jun. 5, 2014; which claims priority to the U.S. provisional application 61/831,445, filed on Jun. 5, 2013, the entire contents of which are hereby incorporated by reference herein in their entireties.The present invention generally relates to proton-binding polymers for oral administration that may be used in the treatment of metabolic acidosis. Metabolic acidosis is the result of metabolic and dietary processes that in various disease states create a condition in which non-volatile acids accumulate in the body, causing a net addition of protons (H+) or the loss of bicarbonate (HCO). Metabolic acidosis occurs when the body accumulates acid from metabolic and dietary processes and the excess acid is not completely removed from the body by the kidneys. Chronic kidney disease is often accompanied by metabolic acidosis due to the reduced capacity of the kidney to excrete hydrogen ions secondary to an inability to reclaim filtered bicarbonate (HCO), synthesize ammonia (ammoniagenesis), and excrete titratable acids. Clinical ...

Proton-binding polymers for oral administration

Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain crosslinked amine polymers and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons and/or chloride ions from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human.

Proton-binding polymers for oral administration

Pharmaceutical compositions for and uses thereof for treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain crosslinked amine polymers and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons and/or chloride ions from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human.

Proton-binding polymers for oral administration

Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain crosslinked amine polymers and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons and/or chloride ions from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human.

Proton-binding polymers for oral administration

Crosslinked poly(allylamine) polymer pharmaceutical compositions

Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain crosslinked amine polymers and may be used, for example, to treat diseases or other metabolic conditions in which removal of a target species from the gastrointestinal tract would provide physiological benefits.

PHARMACEUTICAL COMPOSITIONS OF PROTON-BINDING CROSS-CUTTED AMINE POLYMERS

COMPOSIÇÕES FARMACÊUTICAS DE POLÍMEROS DE AMINA RETICULADOS E USOS DAS MESMAS. Composições farmacêuticas e métodos de tratamento de um animal, incluindo um humano, e métodos de preparação de tais composições. As composições farmacêuticas contêm polímeros de amina reticulados e podem ser usadas, por exemplo, para tratar doenças ou outras condições metabólicas em que a remoção de íons de prótons e/ou cloreto do trato gastrointestinal pode fornecer benefícios fisiológicos, tais como normalização de concentrações de bicarbonato de soro e o pH sanguíneo em um animal, por exemplo, um humano. PHARMACEUTICAL COMPOSITIONS OF CROSS-CUTTED AMINE POLYMERS AND USES THEREOF. Pharmaceutical compositions and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain cross-linked amine polymers and can be used, for example, to treat disease or other metabolic conditions where removal of proton and/or chloride ions from the gastrointestinal tract can provide physiological benefits, such as normalization of bicarbonate concentrations of serum and blood pH in an animal, for example a human.

Proton-binding polymers for oral administration

PROTON BINDING POLYMERS FOR ORAL ADMINISTRATION

Proton-binding polymers for oral administration

Proton-binding polymers for oral administration

Proton-binding polymers for oral administration

Proton-binding polymers for oral administration

Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain crosslinked amine polymers and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons and/or chloride ions from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human.

Πολυμερη συνδεσης πρωτονιου για χορηγηση απο του στοματος

Φαρμακευτικές συνθέσεις για θεραπεία και μέθοδοι θεραπείας ενός ζώου, που συμπεριλαμβάνουν άνθρωπο, και μέθοδοι παρασκευής τέτοιων συνθέσεων. Οι φαρμακευτικές συνθέσεις περιέχουν εγκάρσια συνδεδεμένης αμίνης πολυμερή που μπορεί να χρησιμοποιηθούν για παράδειγμα για να θεραπεύονται ασθένειες ή άλλες μεταβολικές καταστάσεις όπου η απομάκρυνση πρωτονίων ή/και χλωριούχων ιόντων από τη γαστρεντερική οδό θα παρέχει φυσιολογικά οφέλη όπως κανονικοποιημένες συγκεντρώσεις όξινου ανθρακικού του ορού και του pΗ του αίματος σε ένα συμπεριλαμβανομένου ανθρώπου.

Proton-binding polymers for oral administration

Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain crosslinked amine polymers and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons and/or chloride ions from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human.

Proton-binding polymers for oral administration

Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain crosslinked amine polymers and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons and/or chloride ions from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human.

Πολυμερη συνδεσης πρωτονιου για χορηγηση απο του στοματος

Φαρμακευτικές συνθέσεις για θεραπεία και μέθοδοι θεραπείας ζώου, συμπεριλαμβανομένου ανθρώπου, και μέθοδοι παρασκευής τέτοιων συνθέσεων. Οι φαρμακευτικές συνθέσεις περιέχουν εγκάρσια συνδεδεμένα πολυμερή αμίνης και μπορεί να χρησιμοποιηθούν, για παράδειγμα, για να θεραπεύονται ασθένειες ή άλλες μεταβολικές καταστάσεις στις οποίες απομάκρυνση πρωτονίων ή/και χλωριούχων ιόντων από τη γαστρεντερική οδό θα παρέχει φυσιολογικά οφέλη όπως κανονικοποίηση συγκεντρώσεων οξίνου ανθρακικού του ορού και του pΗ αίματος σε ένα ζώο, συμπεριλαμβανομένου ανθρώπου.

Proton-binding polymers for oral administration

Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain crosslinked amine polymers and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons and/or chloride ions from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human.

Crosslinked poly(allylamine) polymer pharmaceutical compositions

Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain crosslinked amine polymers and may be used, for example, to treat diseases or other metabolic conditions in which removal of a target species from the gastrointestinal tract would provide physiological benefits.

Proton-binding polymers for oral administration

81792831 ABSTRACT Provided herein are pharmaceutical compositions and uses thereof for treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain crosslinked amine polymers comprising the residue of an amine corresponding to Formula 1 R1 R2 I R3 Formula 1, and may be formulated for oral administration. The pharmaceutical compositions may be used, for example, to treat diseases or other metabolic conditions in which removal of protons and/or chloride ions from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human. Certain uses include treating an acid/base disorder by removing HCI, and treating metabolic acidosis, for example, in a patient not yet on dialysis. Date Recue/Date Received 2022-07-15

Πολυμερη συνδεσης πρωτονιου για χορηγηση απο του στοματος

Φαρμακευτικές συνθέσεις για θεραπεία και μέθοδοι θεραπείας ενός ζώου, συμπεριλαμβανομένου ανθρώπου, και μέθοδοι παρασκευής τέτοιων συνθέσεων. Οι φαρμακευτικές συνθέσεις περιέχουν εγκάρσια συνδεδεμένης αμίνης πολυμερή που μπορεί να χρησιμοποιηθούν για παράδειγμα για να θεραπεύονται ασθένειες ή άλλες μεταβολικές καταστάσεις όπου η απομάκρυνση πρωτονίων ή/και χλωριούχων ιόντων από τη γαστρεντερική οδό θα παρέχει φυσιολογικά οφέλη όπως κανονικοποιημένες συγκεντρώσεις οξίνου ανθρακικού του ορού και του pΗ του αίματος σε ένα ζώο.

Πολυμερη συνδεσης πρωτονιου για χορηγηση απο του στοματος

Φαρμακευτικές συνθέσεις για θεραπεία και μέθοδοι θεραπείας ζώου, συμπεριλαμβανομένου ανθρώπου, και μέθοδοι παρασκευής τέτοιων συνθέσεων. Οι φαρμακευτικές συνθέσεις περιέχουν εγκάρσια συνδεδεμένα πολυμερή αμίνης και μπορεί να χρησιμοποιηθούν, για παράδειγμα, για να θεραπεύονται ασθένειες ή άλλες μεταβολικές καταστάσεις στις οποίες απομάκρυνση πρωτονίων ή/και χλωριούχων ιόντων από τη γαστρεντερική οδό θα παρέχει φυσιολογικά οφέλη όπως κανονικοποίηση συγκεντρώσεων όξινου ανθρακικού του ορού και του pΗ αίματος σε ένα ζώο, συμπεριλαμβανομένου ανθρώπου.

Processo para preparação de um polímero de amina reticulada

Composições farmacêuticas e métodos de tratamento de um animal, incluindo o ser humano, e métodos de preparo dessas composições. As composições farmacêuticas contêm polímeros de amina reticulados e podem ser usados, por exemplo, para tratar doenças ou outras condições metabólicas, nas quais a remoção de prótons e/ou íons cloreto do trato gastrointestinal proporcionaria benefícios fisiológicos, tais como a normalização das concentrações de bicarbonato sérico e do pH sanguíneo em um animal, incluindo o ser humano.

Composições farmacêuticas de polímero de poli(alilamina) reticulado

sistemas, dispositivos e métodos para produzir implantes protéticos que têm membranas autovedantes para fechamento de furos e prevenção de vazamentos. a presente invenção refere-se a composições farmacêuticas e métodos de tratamento de um animal, incluindo um ser humano, e métodos de preparação de tais composições. as composições farmacêuticas contêm polímeros de amina reticulados e podem ser utilizadas, por exemplo, para tratar doenças ou outras condições metabólicas nas quais a remoção de uma espécie alvo do trato gastrointestinal proporcionaria benefícios fisiológicos.

Crosslinked poly(allylamine) polymer pharmaceutical compositions

Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain crosslinked amine polymers and may be used, for example, to treat diseases or other metabolic conditions in which removal of a target species from the gastrointestinal tract would provide physiological benefits.

Crosslinked poly(allylamine) polymer pharmaceutical compositions

Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain crosslinked amine polymers and may be used, for example, to treat diseases or other metabolic conditions in which removal of a target species from the gastrointestinal tract would provide physiological benefits.

Compositions for and methods of treating acid-base disorders

Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain nonabsorbable compositions and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons, the conjugate base of a strong acid and/or a strong acid from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human.

Compositions for treating acid-base disorders

Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain nonabsorbable compositions and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons, the conjugate base of a strong acid and/or a strong acid from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human.

Polimeros enlazados al proton para administracion oral.

Se describen composiciones farmacéuticas y métodos para tratar un animal, que incluye un humano, y métodos para preparar tales composiciones. Las composiciones farmacéuticas contienen polímeros de amina reticulados y se puede usar, por ejemplo, para tratar enfermedades u otras afecciones metabólicas en las que la eliminación de protones y/o iones de cloruro del tracto gastrointestinal proporcionaría beneficios fisiológicos tal como normalizar las concentraciones de bicarbonato en suero y el pH de la sangre en un animal, que incluye un humano.

Crosslinked poly (allylamine) polymer pharmaceutical compositions

Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain crosslinked amine polymers and may be used, for example, to treat diseases or other metabolic conditions in which removal of a target species from the gastrointestinal tract would provide physiological benefits.

Composiciones farmaceuticas de polimero de poli(alilamina) reticulado.

Composiciones farmacéuticas y métodos para tratar un animal, incluyendo un ser humano, y métodos para preparar las composiciones. Las composiciones farmacéuticas contienen polímeros de amina reticulados y pueden usarse, por ejemplo, para tratar enfermedades u otras afecciones metabólicas en las que la eliminación de una especie objetivo del tracto gastrointestinal proporcionaría beneficios fisiológicos.

Proton-binding polymers for oral administration

Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain crosslinked amine polymers and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons and/or chloride ions from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human.

Proton-binding polymers for oral administration

Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain crosslinked amine polymers and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons and/or chloride ions from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human.